Review Article
Mesenchymal Stem Cells for Cartilage Regeneration of TMJ Osteoarthritis

Dixin Cui,1 Hongyu Li,1 Xin Xu,2 Ling Ye,2 Xuedong Zhou,2 Liwei Zheng,1 and Yachuan Zhou2

1State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Pediatric Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China
2State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan 610041, China

Correspondence should be addressed to Liwei Zheng; liwei.zheng@scu.edu.cn and Yachuan Zhou; iamyczhou@outlook.com

Received 26 July 2017; Accepted 6 September 2017; Published 16 October 2017

Academic Editor: Celeste Scotti

Copyright © 2017 Dixin Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Temporomandibular joint osteoarthritis (TMJ OA) is a degenerative disease, characterized by progressive cartilage degradation, subchondral bone remodeling, synovitis, and chronic pain. Due to the limited self-healing capacity in condylar cartilage, traditional clinical treatments have limited symptom-modifying and structure-modifying effects to restore impaired cartilage as well as other TMJ tissues. In recent years, stem cell-based therapy has raised much attention as an alternative approach towards tissue repair and regeneration. Mesenchymal stem cells (MSCs), derived from the bone marrow, synovium, and even umbilical cord, play a role as seed cells for the cartilage regeneration of TMJ OA. MSCs possess multilineage differentiation potential, including chondrogenic differentiation as well as osteogenic differentiation. In addition, the trophic modulations of MSCs exert anti-inflammatory and immunomodulatory effects under aberrant conditions. Furthermore, MSCs combined with appropriate scaffolds can form cartilaginous or even osseous compartments to repair damaged tissue and impaired function of TMJ. In this review, we will briefly discuss the pathogenesis of cartilage degeneration in TMJ OA and emphasize the potential sources of MSCs and novel approaches for the cartilage regeneration of TMJ OA, particularly focusing on the MSC-based therapy and tissue engineering.

1. Introduction
The temporomandibular joint (TMJ) is a hinge and gliding joint that connects the mandibular condyle with the temporal articular surface. It is one of the most frequently used joints in the human body [1]. Osteoarthritis (OA) is a group of degenerative diseases primarily affecting the joint, characterized by progressive cartilage degradation, subchondral bone remodeling, synovitis, and chronic pain [2, 3]. Osteoarthritis that happened in TMJ often involves degenerations of both hard and soft tissues of TMJ, and patients with TMJ OA usually have joint pain and dysfunction with reduced quality of life. It is estimated that approximately 15% of populations in the world suffer from OA [4]. Epidemiologic studies on the prevalence of TMJ OA differ due to variations in diagnostic criteria, and clinical evidence occurs in 8–16% of populations with symptoms of joint pain, limited occlusion motion, or TMJ sound [5]. Moreover, women have increased susceptibility to the initiation of TMJ OA and induced pain, which occurs mainly after puberty during the reproductive years [6].

The pathogenesis and underlying molecular mechanisms involved in TMJ OA development remain elusive and largely understudied [7, 8]. The treatment strategy for TMJ OA aims at preventing the progressive destruction of cartilage and the subchondral bone, relieving joint pain and restoring TMJ function. The traditional clinical treatments mainly include nonsurgical options, such as physical therapies, occlusal splints, nonsteroidal anti-inflammatory drugs (NSAIDs), and arthrocentesis [9, 10], while surgical intervention is applied to patients with severe symptoms. Although those abovementioned treatments can prevent disease progression...
to a certain degree, they are unable to completely restore degraded cartilage or subchondral bone lesions, as well as disc deteriorations.

Recent years, stem cell-based therapy has aroused a great attention. As a subpopulation of stem cells, mesenchymal stem cells (MSCs) have become vital seed cells for tissue regeneration due to their easy obtainment and multilineage differentiation potential. In addition, the trophic modulations of MSCs exert a biologic function in injured tissues and inflammatory diseases [11, 12]. Combined with appropriate scaffolds via transplantation in vivo, MSCs could restore tissue impairments to form cartilaginous or even osseous compartment in TMJ OA animal models [13, 14]. All these data indicate the capacity of MSCs for the cartilage regeneration in TMJ OA disease.

In this review, we will briefly summarize the pathogenesis of TMJ OA and emphasize the potential of novel approaches for the cartilage regeneration of TMJ OA, particularly focusing on the MSC-based therapy.

2. Pathogenesis of Cartilage Degeneration in TMJ OA

TMJ OA is a highly prevalent degenerative disease affecting articular cartilage as well as other TMJ tissues under pathological conditions and aging process [5]. TMJ condylar cartilage is an avascular, compressible tissue comprised of dense collagen fibres and extracellular proteoglycans, which protect the joint from damage during mechanical loading. The collagen fibres are mainly composed of type I and type II collagen (Col1/Col2) and are well organized to align in an anteroposterior orientation for the resistance to shear stress [15–17]. Chondrocytes embedded in the condylar cartilage are generally separately localized into three layers. Cells in the superficial and middle layers are considered to be progenitor cells with high proliferation capability and differentiation potential. Descending to the deep layer, chondrocytes under terminal differentiation with enlarged, swollen, and vacuolated morphology leading to apoptosis process. Since TMJ OA is a multifactorial disorder [18], understanding of the pathogenesis of cartilage degeneration in TMJ OA could help to identify potential therapeutic targets and interventions.

2.1. Chondrocyte Apoptosis. During TMJ OA progression, articular chondrocytes with low metabolism usually in advance undergo hypertrophy and apoptosis, accompanied with cartilage fibrillation and progressive loss. In cultured TMJ-derived chondrocytes, oxidative stress induced by H$_2$O$_2$ could elevate intracellular reactive oxygen species (ROS) and subsequently induce chondrocyte apoptosis and function impairment [19]. Intra-articular injection of monosodium iodoacetate (MIA) can effectively induce TMJ OA-like phenotype in rats and chondrocyte apoptosis as the most apparent characteristic in cartilage was observed starting from the early stage [20]. Surgical malocclusion induction in another TMJ OA rat models increased chondrocyte autophagy with a reduced activity of mitogen-activated protein kinase kinase kinase kinase-3 (MAP4K3) and mammalian target of rapamycin (mTOR) [21]. Moreover, chondrocyte apoptosis was also illustrated in the initiation stage of TMJ OA in a senescence-accelerated mouse model [22]. Collectively, all these data elucidated the involvement of chondrocyte apoptosis during the initiation and progression of TMJ OA.

2.2. Catabolic Enzymes. In adult healthy cartilage, chondrocytes are in a quiescent state characterized by a fine balance between anabolic and catabolic activities. However, during the disease progression, the condylar chondrocytes demonstrate the progressively decreased synthesis of anabolic components, such as Col2 and aggrecan, the upregulated expression of hypertrophic marker genes, such as Runx2 and ColX, and the increased catabolic enzymes synthesis, such as matrix metalloproteinases (MMPs) [23] and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) [24].

The MMPs belong to a family of proteases and function to degrade extracellular matrix proteins. Among these, MMP-13 is the most important catabolic enzymes involved in cartilage degradation during TMJ OA development. Studies have detected a higher expression of MMP-13 in late-stage OA patients compared with those in the early stage with a lower disease degree [25]. In addition, overexpression of Mmp-13 in transgenic mice has led to degenerative cartilage with excessive Col2 cleavage and aggrecan degradation [23]. Furthermore, mice with the knockout of Mmp-13 rescued surgically induced OA phenotype in knee joint, indicating that the cartilage damage in OA mice model is dependent on MMP-13 activity [26].

The ADAMTS family, particularly ADAMTS4 and ADAMTS5, contributes to the proteoglycan/aggrecan degradation during TMJ arthritis [27]. Inhibition of these enzymes in cultured chondrocytes effectively reduced aggrecan degradation in vitro [28]. The ablation of Adamat5 activity in transgenic mice prevented aggrecan loss and cartilage erosion in inflammation-induced OA models [29]. Similarly, in surgically induced OA mice models, depletion of Adamts5 or double knockout of both Adamts4 and Adamts5 protected against proteoglycan degradation in vitro and decreased the severity of OA progression [30]. Besides, in genetic TMJ OA mouse models, such as β-catenin(ex3)Co12ER mice, rescue effects were also observed by deletion of the either the Mmp-13 or Adamts5 gene [31]. All these evidence suggest that the catabolic enzymes play a key role in the development of TMJ OA.

2.3. Subchondral Bone Remodeling. The abnormal remodeling of the subchondral bone is another pathogenic change contributed to OA in TMJ. Recent studies revealed the interaction between chondrocyte and adjacent osteoclast or osteoblast to regulate the bone-remodeling process [32]. In Camurati-Engelman disease (CED) mice with the systemic skeletal disease, the activated TGF-β signals in the bone marrow developed phenotypes of abnormal bone remodeling, as well as obvious cartilage degradation accompanied by an upregulation of Mmp-9 and Mmp-13 in condylar chondrocytes [33–35]. Besides, several lines of evidence suggested...
that chondrocytes can regulate bone remodeling via RANKL/osteoprotegerin (OPG) signaling. A thinner articular cartilage layer with severe destruction of growth plate cartilage was observed in OPG-deficient mice, indicating that OPG is related to the regulation of cartilage metabolism [36]. Moreover, articular chondrocytes can produce both RANKL and OPG proteins, and different RANKL/OPG ratios may adjust cartilage degradation and subchondral bone remodeling in OA [37, 38]. In malocclusion-induced TMJ OA models, the loss of subchondral bone was observed after 12 weeks, followed by increased expression of osteoclastic factors, such as M-CSF, VEGF, and RUNX, as well as the upregulated RANKL/OPG ratio [37]. To mimic OA environment in vitro, articular chondrocytes were cocultured with peripheral blood mononuclear cells (PBMCs) in vitro. Chondrocytes under the prostaglandin E2 (PGE2) stimulation paracrine secreted RANKL protein to induce osteoclastic activity of monocytes [39]. On the contrary, the β-catenin(n(ex3))CreER mice developed an OA-like phenotype in the knee joint characterized by subchondral bone erosion and osteophyte formation. The activation of β-catenin signals in chondrocytes produced OPG protein to further inhibit osteoclast differentiation by completely binding with RANK on the osteoclasts [40]. Further investigations are needed to elucidate mechanisms governing the interactions between chondrocytes and local bone remodeling; nonetheless, chondrocytes are demonstrated to serve as a link with bone changes in the OA-related process.

Apart from chondrocytes, other pathogenic factors, such as immune cells, cytokines, and hormones, lead to the pathogenetic changes in the subchondral bone. Increasing evidence has demonstrated that synovium inflammation is involved in the progression of OA and associated with joint pain and dysfunction [41, 42]. Various types of immune cells are infiltrated in the inflamed synovium of OA patients. Among these, macrophages are the most abundant cells present in the synovial tissue [43, 44]. In a surgery-induced OA mouse model by intra-articular injections of collagenase into joints, synovial lining macrophages are shown to play a pivotal role in mediating the osteophyte formation during the progression of OA [45]. In cultured synovial cells derived from OA patients, synovial macrophages were specifically depleted from digested synovium using anti-CD14-conjugated magnetic beads. The macrophage depletion resulted in the downregulation of proinflammatory cytokines, such as interleukin (IL-) 6 and IL-8 and MMPs, such as MMP-1 and MMP-3, and it indicated the important role of macrophages in promoting the production of inflammatory and degradative mediators in the OA synovium [46]. Some other studies provided clues about the inhibitory influence on the chondrogenic differentiation of MSCs under the activation of synovial macrophages [47, 48]. Despite the abundance of macrophages, natural killer cells have also been isolated from synovial tissues of OA patients; however, the mechanism involved in the pathogenesis needs to be further elucidated in detail [49].

Along with the infiltration of immune cells, inflammatory cytokines are isolated from the inflamed synovial fluid of patients with TMJ OA, such as IL-1β and tumor necrosis factor- (TNF-)-α [50, 51]. In the experimental chronic inflammation of rodent TMJ induced by intra-articular injections of complete Freund’s adjuvant, increased expressions of IL-1β and TNF-α were detected and supposed to be one cause for the TMJ degenerative changes [52]. Although the administration of TNF inhibitors did not show significant improvement in radiographic scores of patients, individuals have some benefits on joint pain relief and the trends suggested possible targets for the intervention of OA [53]. What is more is that several other cytokines, such as IL-6, have also been shown to be implicated in the progression of TMJ OA [51].

Females especially during the reproductive period have susceptibility to the occurrence of TMJ OA, suggesting that female hormones have a possible involvement in the pathologic changes of condylar cartilage and the subchondral bone. In an iodoacetate-induced TMJ OA rat model, estrogen can aggravate the disease progression by upregulating Fas- and caspase 3-related proapoptotic genes [54]. On the contrary, estrogen could inhibit the expression of nitric oxide to protect TMJ chondrocyte from apoptosis [55]. Thus, the role of estrogen in TMJ OA progression is with controversy and needed more investigations.

3. Mesenchymal Stem Cell-Based Therapy for Cartilage Regeneration of TMJ OA

The treatment for TMJ OA focuses on preventing the destruction of cartilage and subchondral bone, relieving pain, and eventually restoring TMJ function. There are different treatment strategies according to clinical stages of TMJ degeneration, including noninvasive options, such as physical therapies, occlusal splints, NSAIDs, arthrocentesis [9], and surgical intervention, such as joint replacement [56]. Although all these therapies have symptom-modifying and/or structure-modifying effects to some extent, they rarely reverse the disease process to restore the degenerative cartilage and reestablish joint functions.

In recent years, stem cells have been extensively applied to fields of tissue engineering and regenerative medicine [57–59], mainly due to their self-renewal ability and multiple differentiation potentials. Among alternative cell sources for OA treatment, MSCs have raised particular concerns to play a role of seed cells, based on their ease of collection, the potential of chondrogenic differentiation, response to tissue damage, and contributions to tissue turnover. Therefore, extensive progress has been made in the investigation of differentiation potentials and functional modulations of MSCs for cartilage regeneration in TMJ OA treatment.

3.1. Potential of Mesenchymal Stem Cells. MSCs have been identified from various tissues, such as skeletal muscle [60], adipose tissue [61], the placenta [62], the bone [63], the deciduous teeth [64], and the synovium [65]. As the most widely studied sources of MSCs for cartilage regeneration, bone marrow-derived MSCs, synovium-derived MSCs, and umbilical cord-derived MSCs are mainly discussed below.
3.1.1. Bone Marrow-Derived MSCs. MSCs were first identified in the bone marrow via the formation of colonies, represented as colony-forming unit fibroblasts (CFU-F) [66], and bone marrow-derived MSCs (BMSCs) have multilineage differentiation potentials [63], including chondrogenic and osteogenic differentiation.

Studies found that cultured BMSCs preconditioned in osteogenic and chondrogenic media in vitro can form bone-like and cartilage-like structures, respectively, mimicking a primordial joint-like structure when seeded in opposite portions of a hyperhydrated collagen gel via ultrarapid tissue engineering techniques [67]. Some clinical trials have proposed the approaches for OA treatment, which involve the intra-articular injection to deliver BMSCs directly into the synovial fluid compartment [68]. Although most clinical trials participated in the intervention of OA in knee joints, studies on the cartilage regeneration of BMSCs in TMJ OA have been largely investigated. Chen et al. [69] conducted studies on the cartilage regeneration of BMSCs in TMJ OA rabbit models. They also compared that the differentiated MSC-treated group gained better histological scores than the undifferentiated MSC-treated group at an observation period of 4 and 12 weeks, along with decreased expression of MMP-13 and upregulation of Sox9, Col2, and aggrecan. However, the rescue effect displayed no difference in both groups until 24 weeks. Collectively, local delivery of chondrogenic differentiated BMSCs may enhance the regenerative process of cartilage repair at the early stage of TMJ OA through key mediators involved in chondrogenesis. In addition, the implanted cells could be traced by the label of adenoviral vectors containing the LacZ gene, and implanted MSCs were detected within cartilage, subchondral bone, and synovium lasting at least 4 weeks, indicating the involvement of BMSCs in the cartilage repair [69].

Although predifferentiated BMSCs appear to enhance the cartilage regeneration, they do not maintain their proliferative capability and differentiation potentials after prolonged expansion in vitro [70]. In order to attain a better therapeutic outcome, applicable strategies of pretreatment and/or preconditioning of BMSCs are essential to improve long-term effect in OA. Further studies have proved that pretreatment of BMSCs with fibroblast growth factor-2 (FGF-2) [71] and hypoxic preconditioning of BMSCs [72] are two attractive approaches to enhance cell proliferation and chondrogenic differentiation. Whether there are other biophysical approaches needs more investigations to expand the applications of BMSCs in cell-based treatment. Therefore, BMSCs provide an alternative approach for cartilage regeneration; meanwhile, a better application of TMJ OA treatment could be achieved with the pretreatment of BMSCs.

3.1.2. Synovium-Derived MSCs. A number of studies have isolated cells from synovial fluid and synovium in TMJ [73–75], which are able to differentiate into different lineages, such as osteoblasts, chondrocytes, adipocytes, and neurons [73, 76]. These synovium-derived MSCs express MSC markers such as CD90, CD105, and CD73 and negatively express CD11b, CD19, CD34, CD45, and HLA-DR [75], compliant with the widely adopted criteria stipulated by the International Society for Cellular Therapy (ISCT) [77]. Compared with MSCs from other tissues, synovium-derived MSCs possess a greater proliferative rate and superior chondrogenic differentiation potential [78–80]. Particularly, the combination treatment of TGF-β3, dexamethasone, and BMP-2 became the optimum for chondrogenic differentiation of synovium-derived MSCs in vitro [81]. Based on the properties mentioned above, synovium-derived MSCs have been utilized to test the chondrogenic potential for cartilage repair in animal models. In rabbit OA models with defects in whole cartilage layers, synovium-derived MSCs were embedded in collagen gel and transplanted into the injury site. The cartilage defects were repaired with productions of cartilage matrix [82]. The in vivo chondrogenic differentiation of synovium-derived MSCs on cartilage repair have been reported in many other studies [83, 84], leading to a general acceptance that synovium-derived MSCs have the ability to repair cartilage defects to some extent.

The perforation of TMJ disc tissue is usually happening in the late stage of TMJ OA, leading to severe degeneration of condylar cartilage. The application of synovium-derived MSCs for the TMJ disc repair has aroused great attention. A recent study [85] has cultured synovium-derived MSCs on fibrin/chitosan hybrid scaffold under chondrogenic induction combined with TGF-β3 in vitro. In order to evaluate the in vivo repairability, the construct was inserted into the punched TMJ disc explants of rats, which can mimic TMJ disc perforation in human. After 4 weeks of operation, distinct fibrocartilage formation with deposition of Col1 and Col2 was observed at the implantation site. Thus, synovium-derived MSCs are able to repair the defective cartilage in TMJ disc.

3.1.3. Umbilical Cord-Derived MSCs. Apart from adult tissue-derived MSCs, MSCs could also be isolated from the umbilical cord (UC) [86, 87]. Compared with BMSCs, UC-derived MSCs show a more similar gene expression profile to that of embryonic stem cells [88]. They possess a faster proliferative rate and a larger number of CPU-F [89, 90]. The differentiation capacity of UC-derived MSCs into adipogenic, chondrogenic, and osteogenic lineages has been extensively studied [87, 90]. For cartilage tissue engineering, UC-derived MSCs and BMSCs embedded in the polyglycolic acid (PGA) scaffolds and cultured under chondrogenic differentiation medium in vitro. After 3 to 6 weeks, UC-derived MSCs produced more glycosaminoglycans (GAGs) and Col1 than BMSCs, indicating the superior capability of fibrochondrogenesis of UC-derived MSCs [91]. Above all, UC-derived MSCs might be an alternative cell source for the cartilage regeneration.

3.2. Trophic Modulations of MSCs for Cartilage Tissue Regeneration of TMJ. It is well known that MSCs are able to secrete a broad range of bioactive molecules, such as growth factors, cytokines, and chemokines, which constitutes their biological role under injury conditions [92–94]. These trophic factors produced in the MSC-conditioned medium are collectively described as the MSC secretome. Various
MSC-based clinical trials have revealed that transplanted MSCs exert biological functions through trophic modulations rather than differentiation potential [11, 12]. This paradigm shift in the use of MSC-based therapy is becoming a hot issue attracting various studies for better applications to tissue regeneration.

Although TMJ OA is classified as a “low-grade-inflammatory arthritic condition” [9], the involvement of inflammation has been concerned to play a role in disease progression. Several inflammatory cytokines are increased in the synovial fluid of TMJ OA patients, such as IL-12, IL-1β, and TNF-α [51]. Also, the increased expressions of IL-1β and TNF-α were detected in rat TMJ OA models. Particularly, the biomechanical properties of TMJ discs were significantly decreased and the disc ultrastructures were impaired in rodent TMJ OA [52], implying that the chronic inflammation in TMJ OA deteriorates the adaptive ability of the joint. Since MSCs have been explored to regenerate damaged tissue and treat inflammation in many diseases, such as cardiovascular disease, neuron injury, stroke, diabetes, and bone regeneration [95, 96], further studies elucidated that the trophic factors secreted by MSCs exert an anti-inflammatory effect. van Buul et al. added TNF-α and interferon-γ (IFN-γ) to conditioned medium of MSCs to mimic the inflammatory environment of OA. It was found that the increased secretion of secretome decreased expression of the inflammatory gene IL-1β and collagenase genes Mmp-1 and Mmp-13 in response to inflammation [97]. Besides, human BMSCs were intrarticularly injected into rat’s knee joint after hemimeningectomy [97]. Despite the rapid decrease of cell numbers, the human BMSC injection enhanced Col2 expression in the articular cartilage, associated with increased expression of Indian hedgehog (Ihh), parathyroid hormone-like hormone (PTHHLH), and bone morphogenetic protein 2 (BMP2), eventually contributing to the cartilage regeneration and inhibition of OA progression [98]. Furthermore, the periodontal ligament-derived MSCs could increase the cell proliferation and matrix biosynthesis of cocultured TMJ-derived fibrochondrocytes through paracrine secretion of trophic factors [99]. In addition, increased GAG deposition with enhanced expression of chondrogenic genes, such as aggrecan, Col1, and Col2, is also observed in this study.

As a component of secretome, exosomes are demonstrated to play a key role in mediating tissue repair in MSC-based therapy. Exosomes are cell-secreted nano-sized vesicles covered by the bilipid membrane and containing a myriad of regulatory components including microRNAs (miRNAs), mRNAs, and proteins [100–102]. Exosomes can be synthesized in many cells, such as lymphocytes, dendritic cells, and tumor cells, and they are found in most bodily fluids such as blood, urine, and saliva [103]. Diseased cells also secrete exosomes as vehicles to transmit injurious signals, thereby exerting various pathological effects on both recipient and parent cells [104–106]. In MSC-based regenerative therapy, exosomes are widely found in the secretome of MSCs derived from the bone marrow [107, 108], fetal tissues [109], and umbilical cord [110]. To isolate exosomes from secretomes, the conventional culture medium is replaced by medium containing exosome-depleted fetal bovine serum. When BMSCs reach 60–80% confluence, cell culture media are collected and density gradient centrifugations are performed to obtain pellets containing exosomes. The pellets are then passed through a 0.22 μm filter to remove cell debris, and the purified exosomes are obtained [108].

Although the role of the individual components of exosome has not been elucidated, the combined functional complexity of MSC exosomes has therapeutic effects on tissue repair and regeneration in the heart [100], liver [111], skin [112], bone [113], and cartilage [114]. In an experimental rat model with critical-sized osteochondral defects on troclear grooves of the distal femurs, human embryonic MSC-derived exosomes were intra-articularly administrated to investigate the efficacy of exosomes in osteochondral repair. The results showed that over the 12-week period of exosome injections, exosome-treated cartilage and subchondral bone defects were completely restored, characterized by the accelerated neotissue filling and enhanced matrix synthesis of Col2 and sulphated GAG, while only fibrous repair tissues were found in the PBS-treated defects [114]. A recent study conducted the destabilization of medial meniscus (DMM) surgery to induce OA in the knee joints of mice, and the intra-articular injections of exosomes isolated from embryonic MSC medium successfully impeded cartilage destruction in the DMM model. Further in vitro studies using cultured chondrocytes treated with IL-1β illustrated that these exosomes maintained the chondrocyte phenotype by increasing Col2 synthesis and decreasing ADAMTS5 expression, exerting a beneficial therapeutic effect on OA through balancing synthesis and degradation of cartilage extracellular matrix [115]. Among components in the exosome, miRNA might participate in mediating the efficacy of MSC exosome against OA. Exosomal miR-23b could inhibit protein kinase A (PKA) signaling to induce chondrogenic differentiation of human MSCs [116]. Moreover, overexpression of miR-125b in human OA chondrocytes can suppress the IL-1β-induced upregulation of ADAMTS4, and in silico analysis further predicted ADAMTS4 as a putative target gene of miR-125b can be directly regulated in chondrocytes during OA development [117].

All these results demonstrated that the trophic modulations of MSCs play an essential role in the cartilage regeneration in TMJ OA. However, more investigations are needed to figure out the exact effective components among various trophic factors produced by MSCs, which could not only fulfill the current understanding of MSC-based therapy under aberrant environment but also enable allogenic transplantations in a more controlled manner for better applications of tissue regeneration.

3.3. Tissue Engineering Approaches for Cartilage Tissue of TMJ. Based on the rapid development of scaffold materials, the cartilage regeneration of TMJ has been extensively explored in tissue engineering investigations [118–120]. Polyglycolic acid (PGA) is one of the widely applied biocompatible materials in tissue engineering of TMJ cartilage. Studies have proved that PGA enables proliferation of porcine TMJ disc cells, and matrix deposition of ColI was
detected in PGA nonwoven meshes [121, 122]. However, the rapid degradation of PGA is the major demerit leading to the loss of structural/mechanical integrity and construct contraction over time. Due to the defects of PGA, polylactic acid (PLA) has emerged as a more applicable biomaterial for TMJ cartilage regeneration. Porcine TMJ disc cells seeded in PLA had the increased cellularity, with more matrix deposition of collagen and GAGs compared with these in PGA construct [123]. Specifically, adverse construct contraction was not observed in PLA constructs compared to PGA. Another study developed a PLA construct with autologous adipose-derived MSCs predifferentiated in chondrogenic medium. After transplantation in rabbit TMJ, a regular and calcified surface of condyle cartilage was observed, accompanied by the increased expression of Col2 [124].

Except for these scaffolds, syntheses with synthetic polymers, such as PGA and PLA, natural biopolymers, such as fibrin and chitosan, are also applied to the TMJ cartilage regeneration based on their inherent advantage of biocompatibility. A recent study showed that fibrin could improve cell seeding, proliferation, and chondrogenic differentiation in vitro [85]. Moreover, a combination of fibrin/chitosan scaffolds can promote the reparative ability of synovium-derived MSCs, characterized by the fibrocartilage formation with extracellular matrix deposition of Col1, Col2, and GAGs in rat models with TMJ disc explants [85].

In addition to those preceding biopolymers, biologic scaffold materials consisting of extracellular matrix (ECM), such as decellularized urinary bladder matrix (UBM), have aroused great attention in the field of cartilage regeneration. These biologic scaffolds possess constructive remodeling properties by promoting the de novo formation of site-appropriate and functional host tissues, and they are already applied to various preclinical studies and clinical trials [125, 126]. In a canine model of TMJ disectomy, decellularized UBM scaffold acted as an effective interpositional material for the TMJ disc remodeling with no secondary pathologic changes. Of note, the UBM device was further replaced by native tissues, including fibrocartilage, muscle, and connective tissues. This remodeled device consists of elongated fibroblast-like cells within a highly aligned matrix of collagen and site-appropriate soft tissue attachments at the periphery of the implanted material [127].

Considering the pathological features of TMJ OA, emerging investigations have emphasized the pretreatments on the scaffold to construct the stratification of cartilage and the subchondral bone from a single source of MSCs [128]. BMSCs were induced into chondrogenic and osteogenic lineages, and then encapsulated in the stratified polyethylene glycol- (PEG-) based hydrogels to further photopolymerize into human-shaped condyle. After transplantation in vivo, distinct cartilaginous and osseous compartments of the mandibular condyle were formed, with the expression of cartilage-related Col2 and GAGs in the chondral layer and osteogenic markers alkaline phosphatase and osteonectin in the osteogenic layer [13].

Moreover, injectable biomaterial scaffolds have been designed to act as delivery systems containing both cells and biomolecules for more effectively modulating stem cell fate and functions [129, 130]. It has the potential to sustain stem cell survival and signal release [131]. The injectable scaffolds with a lower crosslinked degree and matrix stiffness can promote the chondrogenic differentiation of encapsulated MSCs and increase the matrix biosynthesis of Col2 and GAGs [132]. Furthermore, changes on the mechanical parameters of scaffolds could modulate the MSC differentiation to form different cartilage tissues. MSCs in scaffolds of higher cross-linking degree tend to differentiate into fibroblasts and subsequently form fibrous/osteochondral tissues in the OA rabbit model [133]. Collectively, the scaffold architecture can influence the lineage differentiation of MSCs and the mechanical parameters should be fully estimated to improve MSC-based therapy and tissue engineering.

4. Conclusion

Given the limited self-healing potentials of avascular cartilage, little effective therapy is available for the repair of normal TMJ tissues in OA disease. Although the conventional nonsurgical or surgical treatments can relieve the joint pain to some extent, they cannot completely restore the TMJ function and reverse disease progression. MSCs, which have the multilineage differentiation potentials, may provide an alternative treatment for the cartilage degradation in TMJ OA. Combined with the trophic modulations of MSCs and various scaffold application, the formation of cartilaginous compartment or even stratified cartilaginous and osseous compartments has been accomplished in TMJ OA animal models. Furthermore, continuous investigations are required to detect the target efficiency and biocompatibility in the therapeutic intervention of TMJ OA, hopefully towards the preclinical and clinical researches like in OA treatment.

Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contributions

Dixin Cui and Hongyu Li contributed to work equally.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (NSFC) Grant 81371136 to Xuedong Zhou, NSFC Grant 81470711 to Liwei Zheng, and Technological Innovation Foundation of Sichuan Province 2015TD011 to Ling Ye.

References

[1] S. Rajapakse, N. Ahmed, and A. J. Sidebottom, "Current thinking about the management of dysfunction of the
temporomandibular joint: a review,” *British Journal of Oral and Maxillofacial Surgery*, vol. 55, no. 4, pp. 351–356, 2017.

[2] A. R. Poole, “Osteoarthritis as a whole joint disease,” *HSS Journal*, vol. 8, no. 1, pp. 4–6, 2012.

[3] D. Chen, J. Shen, W. Zhao et al., “Osteoarthritis: toward a comprehensive understanding of pathological mechanism,” *Bone Research*, vol. 5, article 16044, 2017.

[4] C. Egloff, T. Hügel, and V. Valderrabano, “Biomechanics and pathomechanisms of osteoarthritis,” *Swiss Medical Weekly*, vol. 142, article w13583, 2012.

[5] M. Kalladka, S. Quek, G. Heir, E. Elivay, M. Mupparapu, and A. Viswanath, “Temporomandibular joint osteoarthritis: diagnosis and long-term conservative management: a topic review,” *Journal of Indian Prosthodontic Society*, vol. 14, no. 1, pp. 6–15, 2014.

[6] Y. P. Zhao, Z. Y. Zhang, Y. T. Wu, W. L. Zhang, and X. C. Ma, “Investigation of the clinical and radiographic features of osteoarthrosis of the temporomandibular joints in adolescents and young adults,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, vol. 111, no. 2, pp. e27–e34, 2011.

[7] C. Rando and T. Waldron, “TMJ osteoarthritis: a new approach to diagnosis,” *American Journal of Physical Anthropology*, vol. 148, no. 1, pp. 45–53, 2012.

[8] X. D. Wang, J. N. Zhang, Y. H. Gan, and Y. H. Zhou, “Current understanding of pathogenesis and treatment of TMJ osteoarthritis,” *Journal of Dental Research*, vol. 94, no. 5, pp. 666–673, 2015.

[9] R. F. de Souza, C. H. Lovato da Silva, M. Nasser, Z. Fedorowicz, and M. A. Al-Muharraqi, “Interventions for the management of temporomandibular joint osteoarthritis,” *Cochrane Database of Systematic Reviews*, vol. 4, article CD007261, 2012.

[10] W. Zhang, H. W. Ouyang, C. R. Dass, and J. Xu, “Current research on pharmacologic and regenerative therapies for osteoarthritis,” *Bone Research*, vol. 4, article 15040, 2016.

[11] D. van Poll, B. Parekkadan, I. H. M. Borel Rinkes, A. W. Tilles, and M. L. Yarmush, “Mesenchymal stem cell therapy for protection and repair of injured vital organs,” *Cellular and Molecular Bioengineering*, vol. 1, no. 1, pp. 42–50, 2008.

[12] J. Ankrum and J. M. Karp, “Mesenchymal stem cell therapy: two steps forward, one step back,” *Trends in Molecular Medicine*, vol. 16, no. 5, pp. 203–209, 2010.

[13] A. Alhadlaq, J. H. Eliseeffi, L. Hong et al., “Adult stem cell driven genesis of human-shaped articular condyle,” *Annals of Biomedical Engineering*, vol. 32, no. 7, pp. 911–923, 2004.

[14] Y. H. Zheng, K. Su, Y. T. Jian, S. J. Kuang, and Z. G. Zhang, “Basic fibroblast growth factor enhances osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells in coral scaffold constructs,” *Journal of Tissue Engineering and Regenerative Medicine*, vol. 5, no. 7, pp. 540–550, 2011.

[15] M. Singh and M. S. Detamore, “Tensile properties of the mandibular condylar cartilage,” *Journal of Biomechanical Engineering*, vol. 130, no. 1, article 011009, 2008.

[16] P. N. Hirschmann and C. A. Shuttleworth, “The collagen composition of the mandibular joint of the foetal calf,” *Archives of Oral Biology*, vol. 21, no. 12, pp. 771–773, 1976.

[17] M. K. Murphy, R. F. MacBarb, M. E. Wong, and K. A. Athanasiou, “Temporomandibular disorders: a review of etiology, clinical management, and tissue engineering strategies,” *International Journal of Oral & Maxillofacial Implants*, vol. 28, no. 6, pp. e393–e414, 2013.

[18] Y. Zhou, T. Wang, J. L. Hamilton, and D. Chen, “Wnt/β-catenin signaling in osteoarthritis and in other forms of arthritis,” *Current Rheumatology Reports*, vol. 19, no. 9, p. 53, 2017.

[19] T. Ueno, M. Yamada, Y. Sugita, and T. Ogawa, “N-acetyl cysteine protects TMJ chondrocytes from oxidative stress,” *Journal of Dental Research*, vol. 90, no. 3, pp. 353–359, 2011.

[20] X. D. Wang, X. K. Kou, D. Q. He et al., “Progression of cartilage degradation, bone resorption and pain in rat temporomandibular joint osteoarthritis induced by injection of iodoacetate,” *PLoS One*, vol. 7, no. 9, article e45056, 2012.

[21] M. Zhang, J. Zhang, L. Lu et al., “Enhancement of chondrocyte autophagy is an early response in the degenerative cartilage of the temporomandibular joint to biomechanical dental stimulation,” *Cellular Biochemistry and Biophysics*, vol. 63, no. 2, pp. 215–223, 2012.

[22] Y. Ishizuka, Y. Shibukawa, M. Nagayama et al., “TMJ degeneration in SAMP8 mice is accompanied by deranged Ihh signaling,” *Journal of Dental Research*, vol. 93, no. 3, pp. 281–287, 2014.

[23] L. A. Neuhold, L. Killar, W. Zhao et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice,” *The Journal of Clinical Investigation*, vol. 107, no. 1, pp. 35–44, 2001.

[24] W. Li, M. Wu, S. Jiang, W. Ding, Q. Luo, and J. Shi, “Expression of ADAMTS-5 and TIMP-3 in the condylar cartilage of rats induced by experimentally created osteoarthritis,” *Archives of Oral Biology*, vol. 59, no. 5, pp. 524–529, 2014.

[25] B. Bau, P. M. Gebhard, J. Haag, T. Knorr, E. Bartnik, and T. Aigner, “Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro,” *Arthritis & Rheumatology*, vol. 60, no. 10, pp. 2648–2657, 2002.

[26] C. B. Little, A. Barai, D. Burkhardt et al., “Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development,” *Arthritis & Rheumatology*, vol. 60, no. 12, pp. 3723–3733, 2009.

[27] P. Verma and K. Dalal, “ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis,” *Journal of Cellular Biochemistry*, vol. 112, no. 12, pp. 3507–3514, 2011.

[28] A. M. Malfait, R. Q. Liu, K. Iijiri, S. Komiya, and M. D. Tortorella, “Inhibition of ADAMTS-4 and ADAMTS-5 prevents aggrecan degradation in osteoarthritic cartilage,” *Journal of Cellular Biochemistry*, vol. 277, no. 25, pp. 22201–22208, 2002.

[29] H. Stanton, F. M. Rogerson, C. J. East et al., “ADAMTSS is the major aggrecanase in mouse cartilage in vivo and in vitro,” *Nature*, vol. 434, no. 7033, pp. 648–652, 2005.

[30] M. K. Majumdar, R. Askew, S. Schelling et al., “Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis,” *Arthritis & Rheumatology*, vol. 56, no. 11, pp. 3670–3674, 2007.

[31] M. Wang, S. Li, W. Xie et al., “Activation of β-catenin signaling leads to temporomandibular joint defects,” *European Cells and Materials*, vol. 28, pp. 223–235, 2014.

[32] D. M. Findlay and J. S. Kulilwaba, “Bone-cartilage crosstalk: a conversation for understanding osteoarthritis,” *Bone Research*, vol. 4, article 16028, 2016.
[33] Y. Tang, X. Wu, W. Lei et al., “TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation,” *Nature Medicine*, vol. 15, no. 7, pp. 757–765, 2009.

[34] M. Wu, G. Chen, and Y. P. Li, “TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease,” *Bone Research*, vol. 4, article 16009, 2016.

[35] K. Jiao, M. Zhang, L. Niu et al., “Overexpressed TGF-β in subchondral bone leads to mandibular condyle degradation,” *Journal of Dental Research*, vol. 93, no. 2, pp. 140–147, 2014.

[36] N. Amizuka, J. Shimomura, M. Li et al., “Defective bone remodelling in osteoprotegerin-deficient mice,” *Journal of Electron Microscopy*, vol. 52, no. 6, pp. 503–513, 2003.

[37] K. Jiao, L. N. Niu, M. Q. Wang et al., “Subchondral bone loss following orthodontically induced cartilage degradation in the mandibular condyles of rats,” *Bone*, vol. 48, no. 2, pp. 362–371, 2011.

[38] Y. D. Liu, L. F. Liao, H. Y. Zhang et al., “Reducing dietary loading decreases mouse temporomandibular joint degradation induced by anterior crossbite prosthesis,” *Osteoarthritis and Cartilage*, vol. 22, no. 2, pp. 302–312, 2014.

[39] M. J. Martínez-Calatrava, I. Prieto-Potín, J. A. Roman-Blas, L. Tardio, R. Largo, and G. Herrero-Beaumont, “RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis,” *Arthritis Research & Therapy*, vol. 14, no. 3, article R149, 2012.

[40] B. Wang, H. Jin, M. Zhu et al., “Chondrocyte β-catenin signaling regulates postnatal bone remodeling through modulation of osteoclast formation in a murine model,” *Arthritis & Rheumatology*, vol. 66, no. 1, pp. 107–120, 2014.

[41] A. K. Fotinos-Hoyer, A. Guermazi, H. Jara et al., “Assessment of synovitis in the osteoarthritic knee: comparison between manual segmentation, semiautomated segmentation, and semiquantitative assessment using contrast-enhanced fat-suppressed T1-weighted MRI,” *Magnetic Resonance in Medicine*, vol. 64, no. 2, pp. 604–609, 2010.

[42] D. E. Turner, E. Hyslop, R. Barn, I. B. McInnes, M. P. Steultjens, and J. Woodburn, “Metatarsophalangeal joint pain in psoriatic arthritis: a cross-sectional study,” *Rheumatology*, vol. 53, no. 4, pp. 737–740, 2014.

[43] M. J. Benito, D. J. Veale, O. FitzGerald, W. B. van den Berg, and B. Bresnihan, “Synovial tissue inflammation in early and late osteoarthritis,” *Annals of the Rheumatic Diseases*, vol. 64, no. 9, pp. 1263–1267, 2005.

[44] R. Ene, R. D. P. Ene, M. M. Cîrstoiu, and F. C. Cîrstoiu, “Synovial inflammation in patients with different stages of knee osteoarthritis,” *Romanian Journal of Morphology and Embryology*, vol. 56, no. 1, pp. 169–173, 2015.

[45] A. B. Blom, P. L. van Lent, A. E. Holthuysen et al., “Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis,” *Osteoarthritis and Cartilage*, vol. 12, no. 8, pp. 627–635, 2004.

[46] J. Bondeson, S. D. Wainwright, S. Lauder, N. Amos, and C. E. Hughes, “The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis,” *Arthritis Research & Therapy*, vol. 8, no. 6, article R187, 2006.

[47] S. A. Han, S. Lee, S. C. Seong, and M. C. Lee, “Effects of CD14 macrophages and proinflammatory cytokines on chondrogenesis in osteoarthritic synovium-derived stem cells,” *Tissue Engineering Part A*, vol. 20, no. 19-20, pp. 2680–2691, 2014.

[48] N. Fahy, M. L. de Vries-van Melle, J. Lehmann et al., “Human osteoarthritic synovium impacts chondrogenic differentiation of mesenchymal stem cells via macrophage polarisation state,” *Osteoarthritis and Cartilage*, vol. 22, no. 8, pp. 1167–1175, 2014.

[49] B. Moradi, N. Rosshirt, E. Tripel et al., “Unicompartmental and bicompartamental knee osteoarthritis show different patterns of mononuclear cell infiltration and cytokine release in the affected joints,” *Clinical & Experimental Immunology*, vol. 180, no. 1, pp. 143–154, 2015.

[50] R. Vernal, E. Velásquez, J. Gamonal, J. A. García-Sanz, A. Silva, and M. Sanz, “Expression of proinflammatory cytokines in osteoarthritis of the temporomandibular joint,” *Archives of Oral Biology*, vol. 53, no. 10, pp. 910–915, 2008.

[51] L. H. Cevianes, D. Walker, J. Schilling et al., “3D osteoarthritic changes in TMJ condylar morphology correlates with specific systemic and local biomarkers of disease,” *Osteoarthritis and Cartilage*, vol. 22, no. 10, pp. 1657–1667, 2014.

[52] X. D. Wang, S. J. Cui, Y. Liu et al., “Deterioration of mechanical properties of discs in chronically inflamed TMJ,” *Journal and Dental Research*, vol. 93, no. 11, pp. 1170–1176, 2014.

[53] M. D. Magnano, E. F. Chakravarty, C. Boudry et al., “A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands,” *The Journal of Rheumatology*, vol. 34, no. 6, pp. 1323–1327, 2007.

[54] X. D. Wang, X. X. Kou, Z. Meng et al., “Estrogen aggravates iodoacetate-induced temporomandibular joint osteoarthritis,” *Journal of Dental Research*, vol. 92, no. 10, pp. 918–924, 2013.

[55] F. Hu, W. Zhu, and L. Wang, “MicroRNA-203 up-regulates nitric oxide expression in temporomandibular joint chondrocytes via targeting TRPV4,” *Archives of Oral Biology*, vol. 58, no. 2, pp. 192–199, 2013.

[56] M. R. Idle, D. Lowe, S. N. Rogers, A. J. Sidebottom, B. Speculand, and S. F. Worrall, “UK temporomandibular joint replacement database: report on baseline data,” *British Journal of Oral and Maxillofacial Surgery*, vol. 52, no. 3, pp. 203–207, 2014.

[57] A. I. Caplan, “Adult mesenchymal stem cells for tissue engineering versus regenerative medicine,” *Journal of Cellular Physioloogy*, vol. 213, no. 2, pp. 341–347, 2007.

[58] M. Mima and U. K. Batra, “Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies,” *Stem Cells*, vol. 24, no. 11, pp. 2319–2345, 2006.

[59] Y. Y. Chen, S. T. He, F. H. Yan et al., “Dental pulp stem cells express tendon markers under mechanical loading and are a potential cell source for tissue engineering of tendon-like tissue,” *International Journal of Oral Science*, vol. 8, no. 4, pp. 213–222, 2016.

[60] A. Della Valle, G. Maroli, D. Covarello et al., “Pericytes reside in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells,” *Nature Communications*, vol. 2, p. 499, 2011.

[61] W. Tang, D. Zeve, J. M. Suh et al., “White fat progenitor cells reside in the adipose vasculature,” *Science*, vol. 322, no. 5901, pp. 583–586, 2008.
[62] D. T. Covas, R. A. Panepucci, A. M. Fontes et al., "Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts," Experimental Hematology, vol. 36, no. 5, pp. 642–654, 2008.

[63] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells," Science, vol. 284, pp. 143–147, 1999.

[64] M. Miura, S. Gronthos, M. Zhao et al., "SHED: stem cells from human exfoliated deciduous teeth," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5807–5812, 2003.

[65] C. De Bari, F. Dell’Accio, P. Tylzanowski, and F. P. Luyten, "Multipotent mesenchymal stem cells from adult human synovial membrane," Arthritis & Rheumatology, vol. 44, no. 8, pp. 1928–1942, 2001.

[66] A. J. Friedenstein, R. K. Challakakhjan, and K. S. Lalkina, "The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells," Cell and Tissue Kinetics, vol. 3, no. 4, pp. 393–403, 1970.

[67] M. A. Brady, S. Sivananthan, V. Mudera, Q. Liu, J. Wiltfang, and F. Barry and M. Murphy, "The primordium of a biological joint replacement: coupling of two stem cell pathways in biphasic ultrarapid compressed gel niches," Journal of Cranio-Maxillofacial Surgery, vol. 39, no. 5, pp. 380–386, 2011.

[68] F. Barry and M. Murphy, "Mesenchymal stem cells in joint disease and repair," Nature Reviews Rheumatology, vol. 9, no. 10, pp. 584–594, 2013.

[69] K. Chen, C. Man, B. Zhang, J. Hu, and S. S. Zhu, "Effect of in vitro chondrogenic differentiation of autologous mesenchymal stem cells on cartilage and subchondral cancellous bone repair in osteoarthritis of temporomandibular joint," International Journal of Oral and Maxillofacial Surgery, vol. 42, no. 2, pp. 240–248, 2013.

[70] W. S. Toh, "Recent progress in stem cell chondrogenesis," Progress in Stem Cell, vol. 1, no. 1, pp. 7–17, 2014.

[71] A. M. Handorf and W. J. Li, "Fibroblast growth factor-2 primes human mesenchymal stem cells for enhanced chondrogenesis," PLoS One, vol. 6, no. 7, article e22887, 2011.

[72] A. B. Adesida, A. Mulet-Sierra, and N. M. Jomha, "Hypoxia mediated isolation and expansion enhances the chondrogenic capacity of bone marrow mesenchymal stromal cells," Stem Cell Research & Therapy, vol. 3, no. 2, p. 9, 2012.

[73] N. Koyama, Y. Okubo, K. Nakao, K. Osawa, K. Fujimura, and K. Bessho, "Pluripotency of mesenchymal cells derived from synovial fluid in patients with temporomandibular joint disorder," Life Sciences, vol. 89, no. 19-20, pp. 741–747, 2011.

[74] Z. Liu, X. Long, J. Li, L. Wei, Z. Gong, and W. Fang, "Differentiation of temporomandibular joint synovial mesenchymal stem cells into neuronal cells in vitro: an in vitro study," Cell Biology International, vol. 35, no. 1, pp. 87–91, 2011.

[75] Y. P. Sun, Y. H. Zheng, W. J. Liu, Y. L. Zheng, and Z. G. Zhan, "Synovium fragment-derived cells exhibit characteristics similar to those of dissociated multipotent cells in synovial fluid of the temporomandibular joint," PLoS One, vol. 9, no. 7, article e101896, 2014.

[76] I. Futami, M. Ishijima, H. Kaneko et al., "Isolation and characterization of multipotent mesenchymal cells from the mouse synovium," PLoS One, vol. 7, no. 9, article e45517, 2012.
[91] L. Wang, I. Tran, K. Seshareddy, M. L. Weiss, and M. S. Detamore, “A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering,” *Tissue Engineering Part A*, vol. 15, no. 8, pp. 2259–2266, 2009.

[92] S. Meirelles Lda, A. M. Fontes, D. T. Covas, and A. I. Caplan, “Mechanisms involved in the therapeutic properties of mesenchymal stem cells,” *Cytokeine & Growth Factor Reviews*, vol. 20, no. 5-6, pp. 419–427, 2009.

[93] H. Yagi, A. Soto-Gutierrez, B. Parekkadan et al., “Mesenchymal stem cells: mechanisms of immunomodulation and homing,” *Cell Transplantation*, vol. 19, no. 6, pp. 667–679, 2010.

[94] R. J. MacFarlane, S. M. Graham, P. S. Davies et al., “Anti-inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment,” *Expert Opinion on Therapeutic Targets*, vol. 17, no. 3, pp. 243–254, 2013.

[95] D. G. Phinney and D. J. Prockop, “Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views,” *Stem Cells*, vol. 25, no. 11, pp. 2896–2902, 2007.

[96] I. Linero and O. Chaparro, “Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration,” *Porcine One*, vol. 9, no. 9, article e107001, 2014.

[97] G. M. van Buul, E. Villafuertes, P. K. Bos et al., “Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture,” *Osteoarthritis and Cartilage*, vol. 20, no. 10, pp. 1186–1196, 2012.

[98] M. Horie, H. Choi, R. H. Lee et al., “Intra-articular injection of human mesenchymal stem cells (MSCs) promotes rat meniscal regeneration by being activated to express Indian hedgehog that enhances expression of type II collagen,” *Osteoarthritis and Cartilage*, vol. 20, no. 10, pp. 1197–1207, 2012.

[99] J. Zhang, F. Guo, J. Mi, and Z. Zhang, “Periodontal ligament mesenchymal stromal cells increase proliferation and glycosaminoglycans formation of temporomandibular joint derived fibrochondrocytes,” *BioMed Research International*, vol. 2014, Article ID 410167, 8 pages, 2014.

[100] R. C. Lai, F. Arslan, M. M. Lee et al., “Exosomes secreted by MSC reduces myocardial ischemia/reperfusion injury,” *Stem Cell Research*, vol. 4, no. 3, pp. 214–222, 2010.

[101] R. C. Lai, S. S. Tan, B. J. Teh et al., “Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome,” *International Journal of Proteomics*, vol. 2012, Article ID 971907, 14 pages, 2012.

[102] T. S. Chen, R. C. Lai, M. M. Lee, A. B. Choo, C. N. Lee, and S. K. Lim, “Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs,” *Nucleic Acids Research*, vol. 38, no. 1, pp. 215–224, 2010.

[103] M. Yáñez-Mó, P. R. Siljander, Z. Andreu et al., “Biological properties of extracellular vesicles and their physiological functions,” *Journal of Extracellular Vesicles*, vol. 4, article 270066, 2015.

[104] A. G. Thompson, E. Gray, S. M. Heman-Ackah et al., “Extracellular vesicles in neurodegenerative disease — pathogenesis to biomarkers,” *Nature Review Neurology*, vol. 12, no. 6, pp. 346–357, 2016.

[105] I. E. Bank, L. Timmers, C. M. Gijsberts et al., “The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease,” *Expert Review of Molecular Diagnostics*, vol. 15, no. 12, pp. 1577–1588, 2015.

[106] T. Kato, S. Miyaki, H. Ishitobi et al., “Exosomes from IL-1β stimulated synovial fibroblasts induce osteoarthritic changes in articular chondrocytes,” *Arthritis Research & Therapy*, vol. 16, no. 4, article R163, 2014.

[107] M. Nakano, K. Nagaiishi, N. Konari et al., “Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into damaged neurons and astrocytes,” *Scientific Reports*, vol. 6, article 24805, 2016.

[108] Y. Qin, L. Wang, Z. Gao, G. Chen, and C. Zhang, “Bone marrow/stromal/stem/derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo,” *Scientific Reports*, vol. 6, article 21961, 2016.

[109] R. C. Lai, F. Arslan, S. S. Tan et al., “Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles,” *Journal of Molecular and Cellular Cardiology*, vol. 48, no. 6, pp. 1215–1224, 2010.

[110] Y. Zhou, H. Xu, W. Xu et al., “Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro,” *Stem Cell Research & Therapy*, vol. 4, no. 2, pp. 34–46, 2013.

[111] C. Y. Tan, R. C. Lai, W. Wong, Y. Y. Dan, S. K. Lim, and H. K. Ho, “Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models,” *Stem Cell Research & Therapy*, vol. 5, no. 3, p. 76, 2014.

[112] B. Zhang, Y. Yin, R. C. Lai, S. S. Tan, A. B. Choo, and S. K. Lim, “Mesenchymal stem cells secrete immunologically active exosomes,” *Stem Cells and Development*, vol. 23, no. 11, pp. 1233–1244, 2014.

[113] X. Qi, J. Zhang, H. Yuan et al., “Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats,” *International Journal of Biological Sciences*, vol. 12, no. 7, pp. 836–849, 2016.

[114] S. Zhang, W. C. Chu, R. C. Lai, S. K. Lim, J. H. Hui, and W. S. Toh, “Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration,” *Osteoarthritis and Cartilage*, vol. 24, no. 12, pp. 2135–2140, 2016.

[115] Y. Wang, D. Yu, Z. Liu et al., “Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix,” *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 189, 2017.

[116] O. Ham, B. W. Song, S. Y. Lee et al., “The role of microRNA-23b in the differentiation of MSC into chondrocyte by targeting protein kinase A signaling,” *Biomaterials*, vol. 33, no. 18, pp. 4500–4507, 2012.

[117] T. Matsukawa, T. Sakai, T. Yonezawa et al., “MicroRNA-125b regulates the expression of aggrecanase-1 (ADAMTS-4) in human osteoarthritic chondrocytes,” *Arthritis Research & Therapy*, vol. 15, no. 1, article R28, 2013.

[118] C. Chung and J. A. Burdick, “Engineering cartilage tissue,” *Advanced Drug Delivery Reviews*, vol. 60, no. 2, pp. 243–262, 2008.
E. H. Lim, J. P. Sardinha, and S. Myers, "Nanotechnology biomimetic cartilage regenerative scaffolds," *Archives of Plastic Surgery*, vol. 41, no. 3, pp. 231–240, 2014.

M. Liu, X. Zeng, C. Ma et al., "Injectable hydrogels for cartilage and bone tissue engineering," *Bone Research*, vol. 5, article 17014, 2017.

A. J. Almarza and K. A. Athanasiou, "Seeding techniques and scaffolding choice for tissue engineering of the temporomandibular joint disk," *Tissue Engineering*, vol. 10, no. 11-12, pp. 1787–1795, 2004.

K. D. Allen and K. A. Athanasiou, "Tissue engineering of the TMJ disc: a review," *Tissue Engineering*, vol. 12, no. 5, pp. 1183–1196, 2006.

K. D. Allen and K. A. Athanasiou, "Scaffold and growth factor selection in temporomandibular joint disc engineering," *Journal of Dental Research*, vol. 87, no. 2, pp. 180–185, 2008.

K. Ahtiainen, J. Mauno, V. Ellä et al., "Autologous adipose stem cells and polylactide discs in the replacement of the rabbit temporomandibular joint disc," *Journal of the Royal Society Interface*, vol. 10, no. 85, article 20130287, 2013.

S. F. Badylak, B. N. Brown, T. W. Gilbert, K. A. Daly, A. Huber, and N. J. Turner, "Biologic scaffolds for constructive tissue remodeling," *Biomaterials*, vol. 32, no. 1, pp. 316–319, 2011.

S. F. Badylak, D. O. Freytes, and T. W. Gilbert, "Extracellular matrix as a biological scaffold material: structure and function," *Acta Biomaterialia*, vol. 5, no. 1, pp. 1–13, 2009.

B. N. Brown, W. L. Chung, A. J. Almarza et al., "Inductive, scaffold-based, regenerative medicine approach to reconstruction of the temporomandibular joint disk," *Journal of Oral and Maxillofacial Surgery*, vol. 70, no. 11, pp. 2656–2668, 2012.

A. Alhadlaq and J. J. Mao, "Tissue-engineered osteochondral constructs in the shape of an articular condyle," *The Journal of Bone and Joint Surgery*, vol. 87, no. 5, pp. 936–944, 2005.

W. S. Toh, M. Spector, E. H. Lee, and T. Cao, "Biomaterial-mediated delivery of microenvironmental cues for repair and regeneration of articular cartilage," *Molecular Pharmaceutics*, vol. 8, no. 4, pp. 994–1001, 2011.

W. S. Toh and X. J. Loh, "Advances in hydrogel delivery systems for tissue regeneration," *Materials Science and Engineering: C*, vol. 45, pp. 690–697, 2014.

P. M. Mountziaris, P. R. Kramer, and A. G. Mikos, "Emerging intra-articular drug delivery systems for the temporomandibular joint," *Methods*, vol. 47, no. 2, pp. 134–140, 2009.

W. S. Toh, T. C. Lim, M. Kurisawa, and M. Spector, "Modulation of mesenchymal stem cell chondrogenesis in a tunable hyaluronic acid hydrogel microenvironment," *Biomaterials*, vol. 33, no. 15, pp. 3835–3845, 2012.

L. S. Wang, C. Du, W. S. Toh, A. C. Wan, S. J. Gao, and M. Kurisawa, "Modulation of chondrocyte functions and stiffness-dependent cartilage repair using an injectable enzymatically crosslinked hydrogel with tunable mechanical properties," *Biomaterials*, vol. 35, no. 7, pp. 2207–2217, 2014.